Introduction
Breast cancer is the most common cancer in the UK, with 150 women being diagnosed every day. 1 Three quarters of breast cancers contain receptors for estrogen and are known as estrogen receptor positive (ER+). While breast cancer survival rates are increasing, it is still the second most common cause of death from cancer in women. 1 To increase survival rates and reduce the risk of recurrence, many women with ER+ breast cancer are prescribed hormone therapy (HT), such as tamoxifen, or aromatase inhibitors (AIs), which block the effects of estrogen on cancer cells. Five to ten years of HT significantly reduces rates of cancer recurrence and mortality in women with ER+ early breast cancer. 2, 3 Despite significant clinical benefits, many women do not take HT as prescribed, which leads to a significantly increased risk of mortality and recurrence.
Adherence to tamoxifen and AIs ranges from 65% to 79% and 72% to 80%, respectively, but falls over the course of treatment to ~50% by the fourth or fifth year. [7] [8] [9] Furthermore, half of patients discontinue HT by 5 years, 10, 11 suggesting that a significant proportion of patients are not receiving the full clinical benefits of HT. An understanding of the mechanisms behind nonadherence would facilitate development of effective interventions, with a view to improving adherence and ultimately increasing the survival benefits associated with HT. Clinical and demographic factors may be useful as identifiable risk factors but cannot be modified through intervention. Psychosocial factors, however, are typically modifiable and are highly suitable targets for intervention. For example, illness and medication perceptions, such as necessity and concern beliefs, are predictive of adherence in other illnesses 12, 13 and have been successfully modified. 14, 15 A previous review of HT adherence and persistence concluded that little was known about the impact of clinical, demographic, or psychological factors and highlighted a need to research modifiable factors. 16 A significant amount of research has been published since 2012, warranting an upto-date review. In 2015, Cahir et al 17 carried out a systematic review of modifiable determinants of adherence with a view to developing behavioral interventions. Although the review was useful, there were several limitations, which are addressed by the current review. First, the main conclusions were that side effects, the number of prescription medications and the type of practitioner (general practitioner [GP] vs oncologist) influenced HT adherence or persistence. These factors are mostly not suitable for behavior change intervention. A more targeted review of modifiable psychosocial predictors would provide further guidance for the development of an intervention. Second, as gray literature databases and conference abstracts were not included in the search, some key studies are missing from Cahir et al's review. Finally, the authors conducted a meta-analysis, but due to significant heterogeneity, only a very small proportion of studies could be included, limiting the value of the results. For example, although 13 studies investigated the effects of the number of prescription medications, only four studies were eligible for the meta-analysis. Therefore, a narrative synthesis may be more appropriate. Van Liew et al 18 conducted a narrative synthesis concluding that social support, patient-centered interactions, anxiety and medication beliefs were reliably associated with adherence or persistence. However, this review conducted a limited search of only two databases and may have missed some important eligible studies. Furthermore, empirical interest in this area is growing and a considerable number of studies have been published in the 2 years since the previous reviews.
The current review aims to build upon and address limitations in the previous reviews and identify factors related to HT adherence or persistence by: (1) conducting an updated and broader search to ensure that all relevant articles are identified; (2) searching gray literature databases to identify unpublished literature; (3) combining modifiable psychosocial factors with demographic, clinical and health care factors to provide a comprehensive overview of nonadherence and nonpersistence in this population; and (4) conducting a narrative synthesis as opposed to a metaanalysis, due to the anticipated significant heterogeneity within the included studies.
Methods

Search strategy
The review was conducted in accordance with PRISMA guidelines. 19 The following databases were searched from inception to April 2016: MEDLINE, Embase, Web of Science; PsycINFO and CINAHL. Search terms included a combination of terms related to, 1) breast cancer, 2) nonadherence or nonpersistence, and 3) HT. Specific search terms are listed in Table S1 . Reference lists of included articles were screened, and gray literature databases were searched.
Study selection
Inclusion/exclusion criteria are shown in Table 1 . Participants had to be female, .18 years of age and prescribed adjuvant HT for primary breast cancer. Studies had to be conducted in clinical practice, as adherence rates are often higher in clinical trials. 20 After removing duplicates, one author (ZM) 
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Barriers and facilitators of HT adherence screened titles and abstracts and excluded irrelevant articles. Full texts were then screened for inclusion by two authors (ZM and SC) using a predefined screening table, and one disagreement was resolved. Authors of conference abstracts were contacted to identify unpublished articles, and two authors responded with the full-text articles.
Data extraction
Information was extracted on study design, participant characteristics, adherence measurement, outcome measures and study results. Data were extracted by one researcher. Another researcher independently extracted data from 10% of articles, and there were no disagreements.
Quality assessment (QA)
The QA tool was adapted from Pasma et al 21 based on recommendations from Sanderson et al. 22 Studies were assessed on methods for selecting study participants and measuring study variables, appropriate statistical analyses, loss to follow-up and removal of nonpatient-initiated nonadherence (eg, due to contraindications). Studies scored 1 if they met each criterion and 0 if it was not met or was unclear. The proportion of criteria met was indicated by a percentage, as some criteria were not applicable for all articles. One author (ZM) conducted QA, and another author (SC) verified a random subset of 10% of articles. An additional author (LDH) resolved one discrepancy.
Results
A total of 6,140 articles were identified, and after removing duplicates and screening titles and abstracts, 120 full-text articles were screened. Sixty-one articles were included in the review (Figure 1 ). There was heterogeneity between studies in terms of outcome measures, type of effect sizes, definitions of adherence and predictor variables. It is, therefore, inappropriate to conduct a meta-analysis.
Characteristics of studies
The majority of studies were conducted in North America (n=34) and Europe (n=17; Table 2 ). The mean sample size was 3,042 (range 82-26,179), and there were 181,793 unique participants. Two studies included data analyzed 
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Moon et al from the same sample. 23, 24 One study was a follow-up analysis 25 using the same sample as a previous study. 26 All studies were included in the review. Studies were crosssectional (n=16), retrospective (n=32) and longitudinal (n=13). Average follow-up for retrospective and longitudinal studies was 3.1 years (SD =1.4) and 2.7 years (SD =1.4), respectively. Twelve studies included patients prescribed tamoxifen, seven studies included patients prescribed AIs and 42 studies included patients on either therapy. Studies measured nonadherence (n=25), discontinuation/ nonpersistence (n=29), or both (n=6). One study measured interruption, defined as a 60-day gap in treatment. Measurements included Medication Event Monitoring System (MEMS; n=2), medical records (n=4), prescription records (n=27), self-report (n=21) and a combination of measures (n=7). Of the studies using self-report, only six studies used validated measures. Nonpersistence was defined as gaps in treatment of 45 days (n=3), 60 days (n=8), 90 days (n=2) and 180 days (n=6).
Risk of bias in included studies
The average quality score was 74%, ranging from 33% to 100% (Table 3) . The majority of studies were of moderate quality, but there were eleven low-(#50%) and 22 highquality ($80%) studies. Several studies using self-report data had a risk of selection bias, and some studies failed to use validated measures (Table 3) . Only one-third of the studies removed women from analysis who had had a recurrence or died and, therefore, were no longer prescribed HT.
Summary of results
The percentage of women categorized as adherent ranged from 47% to 97% (mean =74%, SD =13%) and fell from an 
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Barriers and facilitators of HT adherence average of 79% in the first year of treatment to 56% in the fourth or fifth year. Studies using MEMS found the highest adherence rate (93%), followed by self-report (82%) and prescription refill rates (75%). Unintentional nonadherence (eg, forgetting) was specifically measured in three studies and was found to be more common than intentional nonadherence (mean =31% vs 15%). [27] [28] [29] Discontinuation ranged from 9% to 63% (mean =30%, SD =12%). Discontinuation rose from an average of 21% in the first year to 48% in the fifth year. Rates of discontinuation were similar across different measurements (prescription refill, self-report and medical records). In some studies, nonpersistence and nonadherence are clearly separated, making it possible to combine the nonpersistence rates (23%-32%) with the nonadherence rates (9%-28%) to calculate the total proportion of the original sample who are not taking their medication as prescribed. In these studies, this amounts to 33%-50% across 2-4 years of treatment, which highlights the extent of the problem of nonadherence in this population.
8,30-32 However, it is not possible to calculate this from other studies due to measurement and classification issues. For example, many studies provide nonadherence figures (using self-report, MEMS and prescription refill) without being explicit as to whether nonpersistent women were removed from analysis or were classed as nonadherent. Others stated that those who discontinued were removed from analysis but have not provided discontinuation rates. Finally, some authors have classed participants who discontinued treatment as nonadherent and some have allowed participants to be both nonpersistent and nonadherent. Therefore, accurate estimates of nonadherence and nonpersistence rates are currently lacking.
Correlates of adherence and persistence
A large number of variables showed no significant relationship with HT adherence or persistence ( Table 4 ). The remaining factors are discussed later. For the purpose of synthesizing results, variables have been classed as having a positive effect, a negative effect, or no effect on adherence/ persistence. A positive/negative effect indicates a statistically significant relationship (P,0.05) between adherence or persistence and the predictor variable.
Clinical factors Adherence
The majority of clinical factors showed no consistent associations with adherence or showed mixed results (eg, tumor size, previous chemotherapy and lymph node status). Switching between HTs was associated with decreased adherence in seven studies 23, 28, [33] [34] [35] [36] [37] and increased adherence in three studies. 8, 38, 39 The majority of articles did not specify the direction of switching between medications.
Regarding overall side effects, two studies showed a negative relationship with adherence 27, 29 and three studies found no significant effects (Table 5) . Hot flushes/vasomotor symptoms, incontinence, gastrointestinal symptoms and sex-related symptoms were not associated with adherence, whereas weight concerns were associated with decreased odds of adherence. 40, 41 Cognitive, gynecological, musculoskeletal and sleep/fatigue-related symptoms were associated with lower odds of adherence in some studies, but the effects were not consistently found. [40] [41] [42] Persistence Similar to adherence, the majority of clinical factors were not reliably associated with persistence for the prescribed treatment duration. Three studies found that a codiagnosis of osteoporosis or diabetes was related to increased persistence. [43] [44] [45] However, mixed results were found for the effects of comorbidities in general, with the majority of studies finding no significant associations.
Five studies found that experiencing any/severe side effects was associated with decreased odds of persistence, 25, 35, [46] [47] [48] but three studies found no significant effects. Women who experienced menopause-related side effects were up to three times less likely to persist 10, 49, 50 in three studies but more likely to persist with treatment in two studies. 48, 51 Hair thinning was associated with increased odds of persistence, but headaches and loss of appetite showed the opposite effect. 51 Gynecological symptoms were associated with increased odds of persistence in one study, 51 but another two studies found no significant effects.
Health care factors Adherence
Consultations with an oncologist or mastologist increased odds of adherence in two studies compared to women without these consultations. 9, 23 Experiencing more hospitalizations was associated with lower odds of adherence. 9, 23, 34, 36 Higher monthly prescription costs were associated with decreased odds of adherence in four studies, 30, 32, 34, 52 but two studies found no significant effects.
Persistence
Five studies showed that odds of persistence increased by 21%-66% if treatment was received by an oncologist or a gynecologist as opposed to a general practitioner, 32, [43] [44] [45] 53 Patient Preference and Adherence 2017:11 submit your manuscript | www.dovepress.com
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Moon et al while two studies found no significant effect. Five studies found that being prescribed more medications per month was associated with increased odds of persistence; 7, 25, 26, 54, 55 however, an additional study showed the opposite effect 32 and three studies found no significant effects. Furthermore, two of the studies showing a positive effect used the same sample at different time points. 25, 26 Three studies found that women who were hospitalized more were less likely to persist with treatment, 24, 56, 57 but one study found no significant effects. Women who used complementary or alternative therapies had lower odds of persistence. 7 
Demographic factors Adherence
Nine studies showed lower odds of adherence for women under the age of 40/50 years, 9, 23, 28, 31, 33, 34, 38, 39, 58 one study found the opposite, 59 and three studies showed no significant effects. Six studies found that older women (.65/75 years) were less likely to be adherent. 9, [30] [31] [32] [33] 59 However, two studies found the opposite effect 28, 60 and six studies found no effects. Four studies found that being black was associated with lower odds of adherence than being white, 8 ,31,32,52 but a further three studies found no significant effects for this relationship.
30,58,61
Persistence
There was a trend suggesting that younger (,45/50 years) women had lower odds of persistence, 8, 24, 43, 45, 54, 60, 62 but this was not always supported. Nine studies showed that older women were less likely to persist with treatment, 8, 11, 30, 32, 48, 54, 57, 62, 63 but seven studies found no significant association and one study found the opposite effect. 49 
Psychosocial factors
The following variables showed significant effects on adherence but were only tested in one study: illness coherence 46 and self-efficacy regarding learning about medication 29 (positive effect on adherence) and practical problems associated with medication taking 29 (negative effect on adherence). Optimism showed a positive effect on persistence, 64 and expressing a future desire for fertility had a negative effect on persistence. 65 
Adherence
There was some evidence suggesting that medication beliefs were related to adherence. Three studies showed that "necessity beliefs", defined as judgments of personal need for the treatment, 12 were significantly related to increased adherence. 35, 66, 67 The adherence estimator measures Predictor variables Number of studies finding positive/negative effect Adherence perceived need for medication, concerns and affordability and categorizes people as low, medium and high risk for nonadherence. Women who were high risk were more likely to report being nonadherent. 42 Negative and positive emotions regarding therapy were related to decreased and increased adherence, respectively, 35, 68 and perceived importance of therapy was related to increased adherence. 61 Karmakar 69 found that coping appraisal, defined as the effectiveness of taking HT and self-efficacy in ability to take HT, minus the costs of taking HT, was associated with increased odds of adherence. Four studies found no effects of necessity beliefs on adherence. 27, 40, 46, 68 These four studies had small sample sizes and may have lacked power to find a significant effect. However, where effect sizes were given, they were relatively small. Three studies found a positive relationship between perceived self-efficacy for medication taking and adherence. 27, 29, 69 Variables relating to patient-physician relationship tended to be associated with adherence. Patient-physician relationship quality, 35 value of doctor's opinion, 61 frequency of physician communication, 67 and self-efficacy in patientphysician communication 27 were positively associated with adherence. However, several of these were only tested in univariate analysis and in single studies.
Persistence
Having a neutral or negative decisional balance score, ie, believing that the benefits of the treatment do not outweigh the harms, was associated with three times lower odds of persistence within the first 2 years of therapy. 26 A 5-year follow-up study supported this relationship but with a smaller effect size. 25 Positive and negative emotions regarding HT were associated with increased/decreased odds of adherence. 35 Results for patient-physician relationship were mixed. Two studies found that perceptions of better physician communication were associated with increased odds of persistence, 50, 64 but three studies found no significant effects. However, one of these effects was nearing significance. 25 Being involved in decisions and discussing HT with a doctor were found to have no significant effects on persistence in two studies and a positive effect in one study. 48 However, being able to ask questions and understanding information, 10 self-efficacy in patient-physician interaction, 50 and receiving the right amount of support 48 were significantly related to increased persistence.
Two studies showed that no longer fearing cancer recurrence was associated with an increased risk of treatment interruption, 10,55 but this did not remain significant in multivariate analysis. 55 Three studies found that women reporting low levels of social support were less likely to persist with treatment. 10, 64, 70 
Discussion
This article reviewed the evidence for clinical, demographic and psychosocial predictors of HT adherence and persistence to present a holistic view of the evidence base. Empirical interest in this area is growing, and this review builds upon previous reviews by incorporating 27 new studies. One previous review concluded that social support, patient-centered interactions, anxiety and beliefs were related to nonadherence/nonpersistence. 18 While this current review supports some of these findings, new research has questioned whether anxiety is related to nonadherence. Cahir et al 17 found that side effects and follow-up care with a GP (vs oncologist) was negatively associated with persistence and the number of medications was positively associated with persistence. This review supported the previous findings that receiving Notes: individual symptoms that were only tested in one study and were not significant are not listed (shortness of breath, eyesight changes, breast sensitivity, fractures/broken bones and retaining water). *The effect was not significant in multivariate analysis or was not tested in multivariate analysis. Abbreviation: HT, hormone therapy.
care from an oncologist was associated with increased persistence but found mixed results for the number of medications and side effects. This review also highlighted new factors, such as younger age and hospitalizations, and moved beyond these findings to identify modifiable factors, such as selfefficacy for medication taking.
Researchers and clinicians often assume that side effects, especially menopausal symptoms, trigger nonadherence. 71, 72 Although some studies found a relationship between side effects and adherence/persistence, the relationship was not always supported. 73 However, studies investigating the effects of hot flushes were low to moderate quality, so further high-quality research is needed. Several studies found that nonadherent or nonpersistent women reported fewer side effects, possibly as a result of not taking the medication. Future research should therefore measure adherence and side effects at several time points to see how the relationship changes across time. Qualitative research has shown that some women would not discontinue HT regardless of its side effects (Moon Z, Moss-Morris R, Hunter M, Hughes L., unpublished data, 2017), which may account for the inconsistent relationship between side effects and adherence.
Being treated by specialists rather than a general practitioner increased persistence. These physicians may provide more specialized and informed care, 43 leading to women being more educated and having positive treatment beliefs, although this was not measured directly. An intervention focusing on knowledge and beliefs may support women who did not receive this from their physician. This is supported by the studies showing that medication beliefs are related to adherence levels. 26, 35 Furthermore, several studies showed that variables relating to the patient-physician relationship and physician communication were associated with increased odds of adherence. These results suggest that training primary care physicians to provide more specialized care could improve adherence rates.
Some evidence suggested that women whose insurance data indicated nonadherence or nonpersistence over 1-5 years were more likely to have been hospitalized over the same period. These women may have not taken their medication while in hospital, but as no data were provided for adherence levels during the hospitalization, no strong conclusions can be made. There was relatively consistent evidence from moderate-to high-quality studies, suggesting that younger women had lower odds of adherence and slightly less consistent evidence for a relationship between younger age and nonpersistence. This is in line with previous reviews into adherence in cancer and other illnesses. 74, 75 Young women may not take HT due to issues around early menopause or fertility 24 as HT precludes conception. In addition, young women do not adjust as well to a cancer diagnosis, which may affect adherence. 54, 76 Results were mixed for the relationship between older age and adherence or persistence.
In terms of modifiable factors, three studies found that women who reported few sources of social support were more likely to discontinue treatment. The importance of social support in maintaining adherence has been highlighted previously, 77, 78 but social support was only found to relate to persistence in this review. Discussing the importance of maintaining good social networks and disclosure of cancer status may increase levels of perceived social support. Several studies have shown promise for the effectiveness of social support interventions. 79, 80 Self-efficacy for medication taking, defined as the patient's confidence in their ability to take the medication as prescribed, was associated with increased odds of self-reported adherence. 27 Self-efficacy for medication taking could be modified by teaching patients strategies to remember to take their medication and helping patients to overcome other practical barriers through modeling, goal setting, or confidence building. Similar interventions have been successful at improving self-efficacy for physical activity and dietary behaviors. 81, 82 Patients who held stronger beliefs regarding how efficacious, necessary, important and affordable HT is were more likely to have higher self-reported adherence, as were women who reported more positive emotions around HT. In addition, women who felt that the risks of the treatment outweighed the benefits were three times more likely to discontinue. This relationship between beliefs and adherence is supported by the Necessity Concerns Framework (NCF) and has been demonstrated previously. 83, 84 The NCF suggests that adherence is related to holding high perceptions of the necessity of the medication and low concerns. These beliefs are often shown to be more powerful predictors of adherence than clinical or sociodemographic characteristics and have been successfully modified through intervention. 35, 83, 85 However, the studies investigating beliefs in this review were low-to moderate-quality cross-sectional studies and some used unvalidated measures. In addition, while medication concerns are often found to be predictive of adherence, 83 the majority of studies found nonsignificant results. This suggests that it may be more important to measure how people weigh up their concerns against their necessity beliefs.
The variability between studies may reflect the heterogeneous populations studied. There were discrepancies in geographic location, health care systems and clinical characteristics. 
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Barriers and facilitators of HT adherence Furthermore, while several studies recruited patients at the initiation of treatment, many studies did not specify the stage of treatment. Research has shown that determinants of adherence vary significantly over time. 10 Therefore, future research should try to recruit patients at the same time point, explicitly state participants' stage of treatment and follow them over the duration of the prescription period.
The results from this review suggest that there are no strong predictors of HT adherence or persistence. Reviewing high-quality studies in isolation (n=22) reflected this pattern of inconsistent results. However, the high-quality studies did support the trend of higher rates of discontinuation in older women and lower adherence in black women, suggesting a need to further investigate these relationships. The majority of predictors investigated, such as age, are not amenable to change through intervention. Future research is needed to identify psychosocial factors that have been shown to impact on adherence in other conditions. For example, illness perceptions have been shown to be predictive of adherence in other illnesses but have not been investigated fully in HT adherence. 12, 86 This review identified one study investigating illness perceptions, which found that coherence beliefs, ie, patients' ratings of their understanding of their breast cancer, were the only significant predictors of nonadherence in multivariate analysis. 46 Self-efficacy for taking medication, social support and medication beliefs provide potential targets for intervention. However, higher quality research is needed in order to clarify the relationship between medication beliefs and adherence. Interventions could also focus on training clinicians and general practitioners to improve patient-physician communication.
There are several limitations to this review. It was not possible to conduct a meta-analysis due to significant heterogeneity between studies. This heterogeneity also makes it difficult to compare across studies and make conclusions based on significant predictors of nonadherence. Although a wide search was conducted and attempts were made to identify gray literature, some relevant articles may not have been identified. The conclusions are limited by the methodological quality of the included studies. There was a risk of selection bias in some studies, which means a subset of the population who are potentially more at risk of nonadherence may not be included. Sixteen studies were cross-sectional which limits assumptions about causality. Two studies used MEMS to measure adherence and found very high levels, most likely due to the Hawthorne effect where adherence increases because patients know that they are being monitored. 87 The most common measurement of adherence and persistence was prescription refill, which is known to be the most objective measure. 88 However, this measurement is still flawed, as we do not know if the patient actually took their medication. Several studies used physician ratings, which are likely to grossly overestimate adherence levels. 89 Self-report measures are also susceptible to overreporting due to social desirability. Four studies overcame these limitations somewhat by using validated questionnaires.
There are several reasons that a patient may be recommended by their physician to discontinue treatment, such as recurrence and contraindications. These patients should not be classified in the same way as women who choose to discontinue HT and should be removed from analysis. Around a third of studies attempted to adjust for this by removing women who had a recurrence or who died. Seven studies did not allow patients to switch medications and still be considered persistent, and 13 studies were unclear as to whether they allowed this. Furthermore, only a few studies have clearly distinguished between nonadherence and nonpersistence and provided independent figures for both. Without this information, it is not possible to determine the full medication-taking behavior of these patients and, therefore, the clinical impact. The behaviors and outcomes of completely stopping treatment and occasionally skipping doses are different, so it is important to understand these as independent with unique predictors. Future research needs to be clear about how nonadherence rates are classified and ideally to provide independent rates for nonadherence and nonpersistence.
Conclusion
Understanding the determinants of nonadherence is essential when designing interventions to improve HT adherence and ensuring that patients realize the full benefits of HT. The main conclusions that can be drawn from this review are that while clinical and demographic factors may be useful in order to identify women at risk of nonadherence, extensive research has not yet identified any consistent predictors. There was some evidence that increased adherence was related to younger age, fewer hospitalizations and better patient-physician relationship, but these relationships were not always supported. Persistence was related to receiving treatment from a specialist. In terms of modifiable factors, there was some evidence to suggest that beliefs about HT, social support and self-efficacy for taking medication were related to adherence and persistence. In order to guide effective interventions to improve HT adherence and persistence, future research should focus on these factors and on identifying additional 
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Moon et al potentially modifiable factors, which have been shown to be related to adherence in other illnesses. 13 Furthermore, strategies to improve patient-physician relationship and service delivery should be investigated.
